-
1 Comment
Zhejiang Jiuzhou Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 22.8% above its 200 day moving average.
From a valuation standpoint, the stock is 37.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.2.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's total revenue rose by 47.5% to $738M since the same quarter in the previous year.
Its net income has increased by 231.4% to $110M since the same quarter in the previous year.
Finally, its free cash flow grew by 1972.4% to $282M since the same quarter in the previous year.
Based on the above factors, Zhejiang Jiuzhou Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | CNE100001W36 |
| Market Cap | 12B |
|---|---|
| PE Ratio | 19.04 |
| Target Price | 25.06 |
| Beta | 0.46 |
| Dividend Yield | None |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization company in China and internationally. The company offers small molecule chemical drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs. It serves global pharmaceutical companies, biotechnology companies, and research institutions. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603456.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
